Literature DB >> 24781417

Regulatory T cells-an important target for cancer immunotherapy.

Jae Il Shin1, Sang-Jun Ha2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24781417     DOI： 10.1038/nrclinonc.2013.208-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  13 in total

1.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors:  Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

2.  Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

Authors:  Qing Zhou; Meghan E Munger; Steven L Highfill; Jakub Tolar; Brenda J Weigel; Megan Riddle; Arlene H Sharpe; Daniel A Vallera; Miyuki Azuma; Bruce L Levine; Carl H June; William J Murphy; David H Munn; Bruce R Blazar
Journal:  Blood       Date:  2010-06-22       Impact factor: 22.113

3.  A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Authors:  Helene Pere; Yves Montier; Jagadeesh Bayry; Francoise Quintin-Colonna; Nathalie Merillon; Estelle Dransart; Cecile Badoual; Alain Gey; Patrice Ravel; Elie Marcheteau; Frederic Batteux; Federico Sandoval; Olivier Adotevi; Christopher Chiu; Sylvie Garcia; Corinne Tanchot; Yu-Chun Lone; Luis Carlos Ferreira; Brad H Nelson; Douglas Hanahan; Wolf Herman Fridman; Ludger Johannes; Eric Tartour
Journal:  Blood       Date:  2011-09-09       Impact factor: 22.113

Review 4.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

5.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Authors:  Stephen R Goding; Kyle A Wilson; Ying Xie; Kristina M Harris; Aparna Baxi; Akgul Akpinarli; Amy Fulton; Koji Tamada; Scott E Strome; Paul Andrew Antony
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

7.  CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

Authors:  Brian Kavanagh; Shaun O'Brien; David Lee; Yafei Hou; Vivian Weinberg; Brian Rini; James P Allison; Eric J Small; Lawrence Fong
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

8.  PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

Authors:  Wenshi Wang; Roy Lau; Daohai Yu; Weiwei Zhu; Alan Korman; Jeffrey Weber
Journal:  Int Immunol       Date:  2009-08-03       Impact factor: 4.823

9.  CTLA-4 control over Foxp3+ regulatory T cell function.

Authors:  Kajsa Wing; Yasushi Onishi; Paz Prieto-Martin; Tomoyuki Yamaguchi; Makoto Miyara; Zoltan Fehervari; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

Review 10.  Strategies to overcome obstacles to successful immunotherapy of melanoma.

Authors:  F Pandolfi; R Cianci; S Lolli; I S Dunn; E E Newton; T J Haggerty; L A Boyle; J T Kurnick
Journal:  Int J Immunopathol Pharmacol       Date:  2008 Jul-Sep       Impact factor: 3.219
View more
  4 in total

1.  Reply: Regulatory T cells-an important target for cancer immunotherapy.

Authors:  Charles G Drake; Evan J Lipson; Julie R Brahmer
Journal:  Nat Rev Clin Oncol       Date:  2014-04-29       Impact factor: 66.675

2.  Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.

Authors:  Valerie Chew; Liyun Lai; Lu Pan; Chun Jye Lim; Juntao Li; Raymond Ong; Camillus Chua; Jing Yao Leong; Kiat Hon Lim; Han Chong Toh; Ser Yee Lee; Chung Yip Chan; Brian K P Goh; Alexander Chung; Pierce K H Chow; Salvatore Albani
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

Review 3.  A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.

Authors:  Zaoqu Liu; Yuqing Ren; Siyuan Weng; Hui Xu; Lifeng Li; Xinwei Han
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

Review 4.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.